Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

Launched by IMPERIAL COLLEGE LONDON · Apr 4, 2024

Keywords

ClinConnect Summary

The MAST Trial is a clinical study designed to see if a treatment called intestinal microbiota transplantation (IMT) can help improve the gut health of patients with certain blood cancers, like leukemia, before they undergo a stem cell transplant. The trial will check how well patients tolerate this treatment compared to a placebo (a harmless pill with no active ingredients) and will look at changes in their gut bacteria, overall health, and outcomes related to their cancer and transplant.

Eligible participants are adults aged 18 and older who have been diagnosed with specific types of leukemia and have completed at least two cycles of chemotherapy. They should be in a condition that allows them to safely receive a stem cell transplant. If you join the study, you'll provide stool, urine, and blood samples during regular follow-up visits, complete some questionnaires, and take either an IMT or placebo capsule two weeks before your stem cell transplant. The goal is to see if restoring gut health can lead to better outcomes during and after the transplant process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. - Patients aged 18 years and over with a morphological documented diagnosis of ALL, acute myeloid leukemia (AML), AL of ambiguous lineage, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and CML in blast phase (Appendix 2) who are deemed fit for allogenic HCT with one of the following disease characteristics: ALL, AML, AL of ambiguous lineage
• • Patients in first complete remission (CR1) or second complete remission (CR2) including complete remission with incomplete blood count recovery with \< 5% blasts (Appendix 2)
• • Secondary leukaemia (defined as previous history of MDS, antecedent haematological disease or chemotherapy exposure) in CR1 or CR2 defined as \< 5% blasts (Appendix 2) MDS and CMML
• • Patients with advanced or high risk MDS with an International Prognostic Scoring System (IPSS-M) moderate high or higher including intermediate or high risk CMML who have \< 5% blasts at the time of randomisation (Appendix 2) CML in blast phase
• • Patients with Philadelphia or BCR:ABL1 positive chronic myeloid leukaemia (CML) in blast phase defined by the presence of ≥ 20% blasts in blood or bone marrow who have achieved second chronic phase with \< 5% blasts (Appendix 2).
• • 2. Patients must have completed minimum of two cycles of intensive chemotherapy prior to trial enrolment (Appendix 1)
• • 3. Patients must have received broad-spectrum antibiotics within 3 months prior to trial enrolment
• • 4. Patients must be considered suitable/fit to undergo allogeneic hematopoietic cell transplantation (HCT) as clinically judged by the Local investigator
• • 5. Patients with an Karnofsky performance status score 60 or above (Appendix 3)
• • 6. Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of commencing therapy until 6 months after treatment
• • 7. Patients have given written informed consent
• • 8. Patients willing and able to comply with scheduled study visits and laboratory tests
• Exclusion Criteria:
• • 1. Patients with contraindications to receiving allogeneic HCT.
• • 2. Female patients who are pregnant or breastfeeding. All women of childbearing potential must have a negative pregnancy test before commencing treatment.
• • 3. Adults of reproductive potential not willing to use appropriate, highly effective, contraception during the specified period.
• • 4. Patients with renal or hepatic impairment as clinically judged by the Local Investigator.
• • 5. Patients with active infection, HIV-positive or chronic active hepatitis B virus (HBV) or hepatitis C virus (HCV).
• • 6. Patients with a concurrent active malignancy or a prior malignancy, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ, incidental histologic finding of prostate cancer (T1a or T1b using the tumour, node, metastasis (TNM) clinical staging system), previous MDS, CMML, Myeloproliferative neoplasms (MPN) resulting in secondary AML. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed.
• • 7. Swallowing difficulties that may preclude safe use of IMT capsules.
• • 8. Administration of IMT within 3 months prior to enrolment (probiotic administration prior to enrolment is allowed but should be recorded at screening).
• • 9. Patients taking probiotics after enrolment to the trial.
• • 10. Gastrointestinal disorders and diseases, including delayed gastric emptying, coeliac disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, chronic diarrhoea, and colonic perforation or fistula.
• • 11. Any autoimmune disease requiring, or that may require, systemic treatment with steroids and/or other immunosuppressants/immunomodulators.
• • 12. Significant bleeding disorder (ALL, AML, AL of ambiguous lineage, MDS, CMML, and CML satisfying inclusion criteria are not excluded).
• • 13. Anaphylactic food allergy.
• • 14. Requirement for vasopressors.
• • 15. Valvular heart disease or known structural defects of the heart.
• • 16. Known severe allergy to capsule components.